RecruitingSchizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Eligible age
18–65 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Sponsor: Neurocrine Biosciences
Where it's recruiting
California
Garden Grove · La Habra · Lemon Grove · Oceanside …
Florida
Hollywood · Maitland · Miami · Tampa …
Georgia
Atlanta
Massachusetts
Boston
Mississippi
Flowood
New York
Cedarhurst · New York · The Bronx
Washington
Bellevue
Source: ClinicalTrials.gov · NCT07227818 · last updated 2026-06-05